BridgeBio Pharma (BBIO) Other Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Other Non-Current Liabilities data on file, last reported at $229000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 34.94% year-over-year to $229000.0; the trailing twelve-month figure through Mar 2026 stood at $229000.0 (down 34.94% YoY), and the FY2025 full-year result was $244000.0, down 14.69% from the prior year.
• Other Non-Current Liabilities slipped to $229000.0 in Q1 2026, from $244000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $28.6 million in Q2 2022 to a low of $229000.0 in Q1 2026.
• A 5-year average of $9.6 million and a median of $679000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 131.05% in 2022 and tumbled 96.8% in 2024, its largest moves.
• Tracing BBIO's Other Non-Current Liabilities over 5 years: stood at $26.6 million in 2022, then slumped by 78.85% to $5.6 million in 2023, then tumbled by 94.92% to $286000.0 in 2024, then decreased by 14.69% to $244000.0 in 2025, then slipped by 6.15% to $229000.0 in 2026.
• Business Quant data shows BBIO's Other Non-Current Liabilities at $229000.0 in Q1 2026, $244000.0 in Q4 2025, and $679000.0 in Q3 2025.